Related by context. All words. (Click for frequent words.) 68 pancreatic adenocarcinoma 68 histological subtype 68 histologic subtype 68 clinicopathologic 68 molecular subtypes 67 unresectable tumors 67 histologies 66 epithelial tumors 66 clinically localized prostate 66 mucinous 66 Medullary thyroid cancer 66 ependymomas 66 tumor histology 66 pituitary adenomas 66 sarcomatoid 66 nodal metastasis 65 hepatic lesions 65 axillary lymph nodes 65 metaplasia 65 urothelial carcinoma 65 radiochemotherapy 65 cervical lymph nodes 65 epithelioid 65 papillary renal cell carcinoma 65 carcinoids 65 pulmonary metastasis 65 nonmetastatic 65 KRAS mutations occur 64 seminomas 64 tumor biopsies 64 ANCA associated 64 histologic subtypes 64 carcinoid 64 breast pancreatic 64 HER2 expression 64 nonmelanoma 64 gastric adenocarcinoma 64 schwannomas 64 PROLARIS 64 GISTs 64 lesional 64 Sjögren syndrome 64 immunohistochemical staining 64 colonic polyps 64 hamartomas 64 axillary lymph node 64 precursor lesions 64 breast carcinoma 64 prostate carcinoma 64 tumor subtypes 64 breast carcinomas 64 prognostic variables 64 metastatic lymph nodes 64 Histologically 64 HER2 positive metastatic breast 63 xenograft models 63 colorectal adenoma 63 renal tumors 63 prostate cancer CaP 63 ovarian lung 63 hepatocellular carcinomas 63 taxane therapy 63 demonstrated antitumor activity 63 prostate carcinomas 63 metastatic gastric 63 Squamous 63 cellularity 63 hormone receptor status 63 Basal cell 63 osteosarcomas 63 metastatic renal 63 mediastinal lymph nodes 63 pulmonary metastases 63 prognostic indicator 63 node metastases 63 EGFR mutation status 63 clinicopathological features 63 FDG uptake 63 Papillary 63 malignant lesions 63 supratentorial 63 K ras mutations 63 serous ovarian cancer 63 colorectal gastric 63 lymphoid tumors 63 stage IIIA 63 breast cancer subtypes 63 skeletal metastases 63 ovarian carcinoma 63 B7 H3 63 sinonasal 63 KRAS mutations 62 osteoid 62 recurrent metastatic 62 Radical prostatectomy 62 gemcitabine carboplatin 62 prognostic indicators 62 patient subpopulations 62 susceptibility loci 62 preclinical xenograft models 62 renal cortical 62 clinicopathological 62 CYT# potent vascular disrupting 62 lung adenocarcinomas 62 tumor xenograft models 62 nonsmall cell lung cancer 62 meningiomas 62 Chronic lymphocytic leukemia 62 papillary 62 demyelinating diseases 62 metastatic bladder 62 neoplasias 62 BCR ABL mutations 62 histopathologic examination 62 HNSCC 62 Myelodysplastic syndromes MDS 62 ductal adenocarcinoma 62 histologic findings 62 T1c 62 methylation markers 62 renal cell carcinomas 62 hematologic malignancies 62 hematologic malignancy 62 histologically confirmed 62 esophagogastric 62 prognostic significance 62 urothelial cancer 62 Hurthle cell 62 molecular abnormalities 62 basal cell carcinoma BCC 62 specific antigen PSA 62 underwent resection 62 pancreatic ovarian 62 T1a 62 carcinoid tumors 62 histologically 62 thyrotropin levels 62 HER2 amplified 62 hematopoietic cancers 62 lymphoma subtypes 62 TTR amyloidosis 62 RRM1 62 ErbB2 positive 62 non squamous NSCLC 62 chronic periodontitis 62 metastatic lesion 61 carcinoid tumor 61 metastatic bone 61 squamous 61 DNA methylation patterns 61 chronic myeloid 61 HIV HCV coinfected 61 benign moles 61 haematologic 61 malignant lymphomas 61 mutated K ras 61 cisplatin resistant 61 hyperplastic 61 distant metastasis 61 thyroid carcinoma 61 neoplasm 61 lymph node metastasis 61 Chronic pancreatitis 61 Lewy bodies DLB 61 prospective multicenter study 61 gastric cardia 61 precancerous tissues 61 gemcitabine Gemzar 61 subtypes 61 renal carcinoma 61 Relapsing remitting MS 61 gastric carcinoma 61 immunocompetent 61 leiomyomas 61 therapeutic regimens 61 histologically proven 61 leiomyoma 61 hA# 61 Leydig cell 61 locoregional recurrence 61 histopathologic findings 61 genetic aberrations 61 squamous histology 61 prophylactic cranial irradiation 61 baseline LDH 61 esophagogastric junction 61 prostate cancer PCa 61 familial clustering 61 oncologic outcomes 61 cutaneous lesions 61 cytoreduction 61 medically inoperable 61 liver metastasis 61 invasive ductal 61 MiCK assay 61 node metastasis 61 Acute myeloid leukemia AML 61 contralateral breast 61 kinase inhibition 61 KRAS status 61 Chronic HCV 61 immunohistochemical 61 pancreatic lung 61 comorbid depression 61 relapsed MM 61 granulomatous 61 metastatic neuroendocrine tumors 61 MGUS 61 prognostic markers 61 Surgical resection 61 hyperintense lesions 61 lymphoid malignancies 61 obstructive coronary artery 61 OnDose TM 61 neoplastic 61 demyelinating 61 leukemia multiple myeloma 61 essential thrombocythemia 61 radiolabeled TM# 61 lymph node metastases 61 primary hyperparathyroidism 61 molecular biomarkers 61 histological diagnosis 61 sonographic findings 61 microsatellite instability 61 malignant pleural mesothelioma 61 metastatic pancreatic 61 histopathologic diagnosis 61 radiographic outcomes 61 lung metastasis 61 tumor xenografts 61 serologic tests 61 malignant neoplasm 61 astrocytomas 61 EGFR HER2 61 recurrent glioblastoma multiforme 61 spontaneous regression 61 pilocytic astrocytomas 61 elevated LDH 61 glial tumors 61 proton MR spectroscopy 61 TRAIL R1 61 MGd 61 chromosomal mutations 61 NMIBC 60 troponins 60 thymic carcinoma 60 adenomatous 60 ischemic cardiomyopathy 60 p# biomarker 60 metastatic lesions 60 hamartoma 60 ipsilateral breast 60 underwent surgical resection 60 Colon polyps 60 tumor regressions 60 ovarian endometrial 60 gastroduodenal 60 breast endometrial 60 aMCI precursor 60 recurrent NSCLC 60 morphologic 60 clinically heterogeneous 60 nondiabetic patients 60 FDG-PET/CT 60 LHRH receptor positive 60 PSA nadir 60 leukemias lymphomas 60 ductal breast cancer 60 histologic 60 serum markers 60 eccrine 60 surgical debulking 60 intra abdominal abscess 60 immunostaining 60 clinico pathological 60 echogenic foci 60 malignant lymphoma 60 invasive lobular 60 Leukemias 60 neoadjuvant treatment 60 #F FDG PET 60 miRview ™ squamous 60 lymphoid cells 60 myeloproliferative diseases 60 multivariate analyzes 60 genomic alterations 60 neovasculature 60 biochemical abnormalities 60 paragangliomas 60 gastrointestinal stromal tumors GISTs 60 completely resected 60 Acute myeloid leukemia 60 hormone receptor negative 60 axillary node dissection 60 hematopoietic malignancies 60 extracranial 60 PNH patients 60 CTEPH 60 tumoral 60 biochemical recurrence 60 deCODE BreastCancer 60 kidney urologic 60 bladder carcinoma 60 resectable 60 standard chemotherapy regimens 60 bronchial epithelial cells 60 gynecologic malignancy 60 hematologic disorders 60 synovial tissue 60 colorectal carcinoma 60 lung carcinomas 60 carotid plaques 60 carcinomatosis 60 prognostic factors 60 tumor subtype 60 atherothrombotic disease 60 diffuse gastric 60 SSc 60 Lung transplantation 60 malignancies 60 HER2 positive cancers 60 FOLFOX regimen 60 hypervascular 60 situ LCIS 60 Epigenomics proprietary 60 mycosis fungoides 60 adnexal masses 60 gastric cancers 60 lymphovascular invasion 60 PRESEPT study 60 lymphoproliferative disorders 60 KRAS mutation 60 thyroid nodules 60 murine model 60 colorectal adenocarcinoma 60 percutaneous biopsy 60 Baseline characteristics 60 sarcoma melanoma 60 adenomatous polyps 60 myelofibrosis polycythemia vera 60 Candida infection 60 lymphadenopathy 60 distinct subtypes 60 malignant pheochromocytoma 60 cystic lesions 60 pathological hallmark 60 rheumatologic 60 macrovascular events 60 angiographically 60 neoplastic lesions 60 resected pancreatic cancer 60 axillary dissection 60 differentiated thyroid 60 KRAS mutant 59 malignant fibrous histiocytoma 59 nonmelanoma skin cancers 59 recurrent ovarian 59 cranial irradiation 59 Prognostic factors 59 neovascular diseases 59 fibroma 59 axilla 59 squamous cell lung cancer 59 mouse xenograft models 59 pancreatic prostate 59 peritoneal cancer 59 F FDG PET 59 CD# expression [002] 59 mesenteric 59 immunohistochemical analysis 59 premalignant lesions 59 Anaplastic 59 small lymphocytic lymphoma 59 pleomorphic 59 chemotherapeutic regimens 59 neuroendocrine cancers 59 metabolomic profiles 59 biologic pathway 59 echocardiographic parameters 59 telomere lengths 59 visceral metastases 59 chemosensitivity 59 deCODE BreastCancer TM 59 liver metastases 59 hepatic cirrhosis 59 calculi 59 extracapsular extension 59 abnormal cytology 59 stage IIIb IV 59 concurrent chemoradiation 59 adjuvant cisplatin 59 Renal Cell Carcinoma RCC 59 intact parathyroid hormone 59 Hodgkin lymphoma HL 59 Azedra 59 myelomas 59 immune dysregulation 59 antitumor efficacy 59 cisplatin vinorelbine 59 hematological disorders 59 idiotype protein 59 rituximab refractory 59 anti angiogenic agents 59 pharmacodynamic parameters 59 Radiofrequency ablation 59 etiologies 59 bronchoalveolar lavage BAL 59 relapsed SCLC 59 carotid stenosis 59 cisplatin chemotherapy 59 extramedullary 59 preoperative chemotherapy 59 postoperative complication 59 parenchymal 59 ductal carcinomas 59 lobular carcinomas 59 adjuvant systemic 59 metachronous 59 Multivariate logistic regression 59 Soft tissue sarcomas 59 FDG PET imaging 59 soft tissue sarcomas 59 adenocarcinoma histology 59 missense mutations 59 histopathologic 59 xenograft tumors 59 malignant prostate 59 pathologic diagnosis 59 oligodendrogliomas 59 PCNSL 59 angiographic outcomes 59 pituitary adenoma 59 normal karyotype 59 pT2 59 Endometrial cancer 59 Basal Cell 59 localized renal 59 Oncotype 59 hepatorenal syndrome 59 antiangiogenic agents 59 NSCLC tumors 59 stage IIIB IV 59 gefitinib Iressa 59 CIN2 + 59 MALT lymphoma 59 underlying pathophysiology 59 non squamous 59 SLNB 59 hematologic cancers 59 mesotheliomas 59 TTF Therapy 59 KRAS wild 59 etiologic 59 Comorbidities 59 urolithiasis 59 Immunohistochemical staining 59 colon pancreatic 59 CDH1 59 BEXXAR Therapeutic Regimen 59 Neoadjuvant chemotherapy 59 polypoid 59 debulking surgery 59 thymectomy 59 affective psychosis 59 hypermethylated 59 operable breast cancer 59 neuroendocrine carcinoma 59 basal cell skin 59 motor neuron degeneration 59 gastroesophageal junction 59 pulmonary nodules 59 lymph node enlargement 59 aerodigestive tract 59 pleural fluid 59 radiotherapy RT 59 atypical hyperplasia 59 HER2 overexpression 59 minimally symptomatic 59 necrotic core 59 evaluating REVLIMID 59 endocervical 59 lymphatic tissue 59 tumor necrosis 59 histologic diagnosis 59 #.#ng/ml 59 mammographically 59 locoregional 59 EGFR mutations 59 preoperative staging 59 RECIST Response Evaluation Criteria 59 RET PTC rearrangements 59 adjuvant therapies 59 myeloproliferative disorders 59 deCODE ProstateCancer TM 59 prostatic tissue 58 PCA3 scores 58 fallopian tube carcinoma 58 etiologic factors 58 nomograms 58 refractory metastatic 58 invasive carcinoma 58 lymphadenectomy 58 alkylating 58 nasopharyngeal carcinoma 58 HBeAg negative 58 pCR 58 advanced adenomas 58 gallium nitrate 58 MAPK pathway 58 Sezary syndrome 58 murine models 58 ovarian pancreatic 58 chest radiographs 58 spinal metastases 58 T2 lesions 58 autosomal dominant polycystic kidney 58 miRNA expression 58 Response Evaluation Criteria 58 lobular 58 neoplasms 58 heavily pretreated 58 pegylated liposomal doxorubicin 58 surgically resected 58 ependymoma 58 neovascular 58 Virulizin ® 58 lymphocytic 58 somatic mutations 58 miRNA expression patterns 58 atherothrombosis 58 thymoma 58 osteochondromas 58 endobronchial 58 allogeneic HSCT 58 IgG1 antibodies 58 candidemia 58 trastuzumab Herceptin ® 58 radiosensitive 58 EGFR mutant 58 Adverse effects 58 peritoneal carcinomatosis 58 gp# protein [002] 58 neurocognitive impairment 58 ADPKD 58 adnexal mass 58 thoracoscopic lobectomy 58 Adjuvant chemotherapy 58 circulating endothelial cells 58 Wilms tumors 58 genetic determinants 58 autonomic dysfunction 58 relapsed mantle 58 LVNC 58 dyslipidaemia 58 multivessel coronary artery 58 prognostic factor 58 glycosylated hemoglobin levels 58 radiographic findings 58 monoclonal gammopathy 58 resected tumors 58 digital subtraction angiography 58 lipid lowering agents 58 carcinoma HCC 58 hypercoagulable 58 prognostic biomarker 58 CTAP# Capsules 58 colorectal polyp 58 glioblastoma multiforme GBM 58 pancreatic colon 58 perfusion abnormalities 58 adverse cytogenetics 58 fluconazole resistant 58 non squamous histology 58 HCV genotypes 58 euthymic patients 58 lung resection 58 pancreatic endocrine 58 hepatic metastases 58 antiproliferative effects 58 pleiotropic effects 58 epithelial ovarian cancer 58 invasive ductal breast cancer 58 Histologic 58 extracolonic 58 cytogenetic responses 58 ovarian breast 58 postoperative chemotherapy 58 myelogenous leukemia 58 benign neoplasms 58 Estrogen Receptor 58 basal cell nevus syndrome 58 galiximab 58 carotid bruit 58 external beam radiotherapy 58 Diffuse Large B 58 refractory Hodgkin 58 tertile 58 KRAS variant 58 nodal metastases 58 Rectal cancer 58 Diabetic nephropathy 58 colorectal lung 58 isotypes 58 lymphomas leukemias 58 biliary cancer 58 malignant ovarian 58 pretransplant 58 response pCR 58 antiangiogenic therapy 58 curability 58 prostate adenocarcinoma 58 histopathological 58 choroid 58 macroalbuminuria 58 LHRH antagonists 58 sCJD 58 preoperative PSA 58 lymph node dissection 58 BCG refractory 58 AML acute myeloid 58 HER2 amplification 58 bronchogenic carcinoma 58 mutated p# 58 hepatocellular carcinoma liver 58 endoscopic ultrasonography 58 myeloproliferative neoplasms 58 pain palliation 58 Epithelial ovarian cancer 58 FFR measurements 58 BPS IC 58 Brain metastases 58 genetic polymorphisms 58 thetreatment 58 colorectal neoplasms 58 invasive lobular carcinoma 58 osteoblastic 58 tertiles 58 pT3 58 Recurrence Score 58 metastatic liver 58 neurologic complications 58 cerebrospinal fluid CSF 58 nonischemic 58 grade cervical intraepithelial 58 malignant nodules 58 Waldenstrom macroglobulinemia 58 lymph node involvement 58 familial pancreatic cancer 58 lung lesions 58 urothelial 58 dosage regimens 58 farletuzumab 58 gastrointestinal stromal tumor GIST 58 Secondary efficacy endpoints 58 BRAF V#E 58 mechanistic studies 58 Gastrointestinal Stromal Tumors 58 pediatric acute lymphoblastic 58 squamous cell histology 58 sorafenib Nexavar ® 58 Non Hodgkin lymphomas 58 idiopathic PAH 58 metabolic parameters 58 Hematologic 58 chronic lymphocytic 58 endometrioid 58 ASCUS 58 acute leukemias 58 atypical ductal hyperplasia 58 endocrine therapies 58 N. gonorrhoeae 58 LV dysfunction 58 morphometric vertebral fractures 58 ocular melanoma 58 malignant cancerous 58 neoadjuvant therapy 58 Randomized trials 58 surgically resectable 58 taxane chemotherapy 58 epithelia 58 comorbid disorders 58 hypertrophic scars 58 Histopathologic 58 prognostic marker 58 FDG PET 58 eTag assays 58 epithelial ovarian 58 ConclusionThis 58 plexiform 58 Lymphomas 58 PITX2 58 Chronic lymphocytic leukemia CLL 58 IV NSCLC 58 oral squamous cell 58 Lymph node 58 androgen deprivation 58 Alequel 58 inflammatory biomarkers 58 bladder ovarian 58 atherosclerotic disease 58 differential gene expression 58 chemotherapy regimens 58 T1DM 58 immunomodulatory therapy 58 lymph node removal 57 HRCT 57 electrophysiologic 57 methylation patterns 57 vascular dysfunction 57 tolerability pharmacokinetics 57 cytologic 57 endometrial ovarian 57 lobular breast cancer 57 CIMZIA TM certolizumab pegol 57 EGFR mutation positive 57 leukemia AML 57 CSF biomarkers 57 metastatic renal cell 57 Doppler sonography 57 serum PTH 57 fluoroquinolone resistance 57 Hepatocellular Carcinoma HCC 57 transthyretin amyloidosis 57 previously untreated follicular 57 TMPRSS2 ERG 57 epithelial tissues 57 gross hematuria 57 postoperative mortality 57 transgene expression 57 HAAH 57 nodular melanoma 57 haematopoietic 57 ductal 57 myocardial viability 57 Non Hodgkins lymphoma 57 atherothrombotic 57 rituximab refractory follicular 57 polycythemia vera PV 57 HG PIN 57 microRNA expression 57 ER CHOP 57 recurrent malignant glioma 57 constipation OIC 57 EGFR inhibition 57 oral Hycamtin 57 tissue microarrays 57 pulmonary infiltrates 57 SUVmax 57 SEER database 57 trans retinoic acid 57 hematological relapse 57 sclerosing 57 pre malignant lesions 57 telomerase inhibition 57 orchitis 57 cancer mCRC 57 multiple myeloma MM 57 lenalidomide dexamethasone 57 genes differentially expressed 57 CIN3 57 cholangiocarcinoma 57 Transverse myelitis 57 proximal colon 57 Tumor Response 57 ALB # 57 superficial bladder cancer 57 lung pancreatic 57 hypervascular tumors 57 clinically meaningful improvements 57 transplantation HCT 57 multivariable analyzes 57 liposomal doxorubicin 57 postoperative radiotherapy 57 papillomas 57 diabetes mellitus DM 57 hematological diseases 57 intracranial hemorrhage ICH 57 pharmacodynamic PD 57 faulty BRCA genes 57 predictive biomarker 57 hematological parameters 57 paricalcitol 57 dose proportional pharmacokinetics 57 HLA DR 57 microarray experiments 57 neurosensory 57 fibrotic disease 57 estrogen receptor ER 57 PSADT 57 metastatic malignant 57 nonalcoholic steatohepatitis 57 SIADH 57 intraperitoneal chemotherapy 57 virologic responses 57 dysplastic lesions 57 Kaplan Meier curve 57 Venous thromboembolism 57 colorectal neoplasia 57 pelvic lymphadenectomy 57 standard chemotherapy regimen 57 follicular lymphoma FL 57 cirrhosis liver failure 57 DCE MRI 57 left ventricular diastolic 57 syndromal 57 T2 weighted images 57 genetic loci 57 adrenocortical cancer 57 chronicity 57 endometrial carcinoma 57 Ribavirin causes 57 leukemia myeloma 57 Alessandro Riva 57 ansamycin 57 curative resection 57 Sentinel node biopsy 57 gynecological malignancies 57 serum GGT 57 leukaemias 57 steatohepatitis 57 Doxil ® 57 heavily pretreated patients 57 circadian genes 57 neurofibroma 57 colorectal liver metastases 57 tumor metastases 57 TNM staging 57 smoldering myeloma 57 cediranib 57 cytoreductive surgery 57 pharmacodynamic endpoints 57 stratifying patients 57 Cardiotoxicity 57 pathologic 57 breast lesions 57 affective psychoses 57 atherosclerotic vascular disease 57 gastric carcinomas 57 cytologically 57 lipomas 57 fibrin deposition 57 hypoperfusion 57 panobinostat 57 haematological malignancies 57 stereotactic radiotherapy 57 relapsing remitting MS RRMS 57 immuno modulatory 57 autoimmune pancreatitis 57 CP CPPS 57 nonalcoholic steatohepatitis NASH 57 pathophysiological mechanisms 57 atherogenic dyslipidemia 57 cardiac allograft vasculopathy 57 palliative radiotherapy 57 comorbid diagnoses 57 hyperacute 57 conformal radiotherapy 57 hormone refractory 57 gene polymorphisms 57 peritumoral 57 Prostatic 57 p# mutations 57 BRAF mutations 57 gadolinium enhanced 57 epithelial cancers 57 nodular 57 seminoma 57 anti JCV antibodies 57 KRAS gene mutations 57 gene expression profiles 57 latent celiac disease 57 adenocarcinomas 57 follicular lymphomas 57 essential thrombocythemia ET 57 melanoma ovarian 57 Ph + acute lymphoblastic 57 hemoglobinopathies 57 metastatic colorectal 57 ADVEXIN therapy 57 biliary tract cancer 57 erythema nodosum 57 osteoid osteoma 57 enzastaurin 57 malignant pleural mesothelioma MPM 57 anaplastic astrocytoma AA 57 esophageal squamous cell carcinoma 57 chemoembolization 57 neurofibromas 57 lumbar disk herniation 57 hematologic parameters 57 Hp2 2 57 hypertension hypercholesterolemia 57 p#HER# 57 mixed hyperlipidemia 57 chemoresistant 57 biologic pathways 57 Chronic Lymphocytic Leukemia CLL 57 HER2 positive breast 57 gastrointestinal malignancies 57 prognostically 57 Subgroup analyzes 57 hepatocellular 57 paclitaxel eluting stents 57 INCB# [003] 57 spirometric 57 MADIT CRT trial 57 Menopausal hormone therapy 57 systemic anaplastic large 57 mutated KRAS 57 GBM tumors 57 grade gliomas 57 GPC5 57 Sarcomas 57 Gleevec resistant 57 aminotransferases 57 transfusion syndrome 57 gene deletions 57 tissue microarray 57 lobular carcinoma 57 International Prognostic Scoring 57 appendiceal 57 metastatic lung cancer 57 KRAS oncogene 57 Toxicities 57 ragweed allergic 57 acute myeloid 57 liver transplant recipients 57 Squamous cell 57 Gliadel Wafer 57 Cholangiocarcinoma 57 prospectively stratified 57 System IPSS 57 EGFR inhibitors 57 FGFR2 gene 57 Anthracycline 57 differentiate squamous 57 intratumoral 57 microbleeds 57 BRCA mutation carriers 57 plain radiographs 57 stage IIIB 57 immunological diseases 57 Metastases 57 benign nodules 57 endometrial cancers 57 clonogenic 57 anemia thrombocytopenia 57 hemodynamic measurements 57 artery stenosis 57 erlotinib Tarceva ® 57 antiangiogenic activity 57 FOLPI 57 alanine aminotransferase ALT 57 EBUS FNA 57 iniparib BSI 57 coronary stenosis 57 OHR/AVR# 57 Chronic Myelogenous Leukemia CML 57 BRCA1 BRCA2 56 pancreatic ductal 56 anti angiogenic therapy 56 systemic lupus erythematosus SLE 56 chemotherapy cisplatin 56 Glioblastomas 56 pheochromocytoma 56 HbF 56 obese postmenopausal 56 biochemical relapse 56 atypical hemolytic uremic syndrome 56 carcinomas 56 cardiac perfusion 56 grade glioma 56 HepG2 cells 56 invasive carcinomas 56 RQ PCR 56 genotypic resistance 56 neoplastic diseases 56 arterial thickening 56 esophageal carcinoma 56 #q# deletion 56 testicular germ cell 56 immunomodulation 56 Carcinoid tumors 56 paraganglioma 56 cTnT 56 Mutational 56 haematological 56 imatinib resistance 56 intracranial tumors 56 duplex ultrasonography 56 neuritic 56 neurological manifestations 56 nonhereditary 56 intracerebral haemorrhage 56 squamous cell carcinoma SCC 56 monogenic 56 FluCAM arm 56 ischemic lesions